Accuray Incorporated (LON:0H8I)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 19.40M -86.9% |
| Revenue (ttm) | 302.95M -12.3% |
| Net Income | -37.08M |
| EPS | -0.30 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,054 |
| Open | 0.2270 |
| Previous Close | 0.2249 |
| Day's Range | 0.2201 - 0.2300 |
| 52-Week Range | 0.2200 - 2.2000 |
| Beta | 1.39 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About Accuray
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidn... [Read more]
Financial Performance
In fiscal year 2026, Accuray's revenue was $401.95 million, a decrease of -12.34% compared to the previous year's $458.51 million. Losses were -$49.19 million, 2992.0% more than in 2025.
Financial numbers in USD Financial StatementsNews
Accuray Proxy statement: Proxy filing
Accuray filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
MADISON, Wis., Sept. 11, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, and RaySearch Laboratories AB (publ) today anno...
Accuray Registration statement: Registration filing
Accuray filed a registration statement on September 9, 2026, providing details about a securities offering with the SEC.
Accuray Proxy statement: Proxy filing
Accuray filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
Accuray Registration statement: Registration filing
Accuray filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Accuray Earnings Call Transcript: Q4 2026
Fiscal 2026 saw significant transformation, with strengthened financials, improved service margins, and new strategic partnerships, despite revenue declines driven by lower product sales and macroeconomic headwinds. The TCW transaction enhances liquidity and flexibility for future growth.
Accuray Earnings release: Q4 2026
Accuray released its Q4 2026 earnings on August 19, 2026, summarizing the period's financial results.
Accuray Slides: Q4 2026
Accuray has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on August 19, 2026.
Accuray Annual report: Q4 2026
Accuray has published its Q4 2026 annual report on August 19, 2026.
Accuray reports Q4 EPS (2c) vs. 1c last year
Reports Q4 revenue $100.9M vs. $127.5M last year. “Fiscal 2026 was a transformational year for Accuray (ARAY). Throughout the year, we strengthened our operational foundation, improved accountability ...
Accuray: Operating from a position of greater strength than a year ago
As the company enters fiscal 2027, management believes Accuray (ARAY) is operating from a position of greater strength than a year ago. The company expects continued growth in service revenue,…
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results
MADISON, Wis., Aug. 19, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2026, ended June 30, 2026.
Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments
MADISON, Wis., Aug. 12, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced two key leadership appointments intended to improve operational execution and profitability, deliver increase...
Accuray Proxy statement: Proxy filing
Accuray filed a proxy statement on August 12, 2026, providing details for shareholder voting and corporate governance matters.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
MADISON, Wis., Aug. 5, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2026, ended June 30, 2026, during a conference call ...
Accuray Registration statement: Registration filing
Accuray filed a registration statement on July 31, 2026, providing details about a securities offering with the SEC.
Accuray files to sell 6.83M shares of common stock for holders
07:04 EDT Accuray (ARAY) files to sell 6.83M shares of common stock for holders
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
MADISON, Wis., July 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced a plan incorporating several dec...
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
MADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Com...
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collabo...
Accuray downgraded to Hold from Buy at Jefferies
Jefferies analyst Young Li downgraded Accuray (ARAY) to Hold from Buy with a price target of 35c, down from $3.05. The firm cites the company’s fiscal Q3 miss and the…
Accuray downgraded to Neutral from Buy at BTIG
BTIG downgraded Accuray (ARAY) to Neutral from Buy without a price target The company is ahead of schedule on its cost-cutting efforts, but its product revenue is being held back…
Accuray reports Q3 EPS (9c) vs. (1c) last year
Reports Q3 revenue $104.8M vs. $113.2M last year. “During the quarter, we made meaningful progress executing against the transformation plan we launched in December,” said CEO Steve LaNeve. “We are…
Accuray Earnings Call Transcript: Q3 2026
Q3 FY2026 revenue declined 7% year-over-year due to geopolitical disruptions and macro headwinds, prompting withdrawal of financial guidance. Transformation initiatives are ahead of schedule, with $10 million in improvements realized and further benefits expected in FY2027.
Accuray Earnings release: Q3 2026
Accuray released its Q3 2026 earnings on May 6, 2026, summarizing the period's financial results.